YOSEMITE

E827934

YOSEMITE is a phase III clinical trial evaluating the efficacy and safety of faricimab in patients with diabetic macular edema.

Jump to: Statements Referenced by

Statements (26)

Predicate Object
instanceOf clinical trial
phase III clinical trial
controlComparator aflibercept
drugClassEvaluated bispecific antibody
endpointCategory anatomical retinal outcomes
safety and tolerability
visual acuity outcomes
evaluatesCondition diabetic macular edema
evaluatesDrug faricimab NERFINISHED
evaluatesIndication diabetic macular edema
indicationCategory diabetic eye disease
population adult patients with diabetic macular edema
primaryObjective evaluate efficacy of faricimab in diabetic macular edema
routeOfAdministration intravitreal injection
secondaryObjective evaluate safety of faricimab in diabetic macular edema
sponsor Genentech NERFINISHED
Roche NERFINISHED
studyDesign active-controlled
double-masked
multicenter
randomized
studyType interventional
targetsPathway Angiopoietin-2 NERFINISHED
VEGF-A NERFINISHED
therapeuticArea ophthalmology
trialPhase Phase III

Referenced by (1)

Full triples — surface form annotated when it differs from this entity's canonical label.

faricimab clinicalTrial YOSEMITE